Colin Bristow
Stock Analyst at UBS
(1.08)
# 3,590
Out of 4,761 analysts
88
Total ratings
29.63%
Success rate
-12.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $6.29 | +11.29% | 2 | Feb 14, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $4 → $2.2 | $1.12 | +96.43% | 5 | Jan 27, 2025 | |
| PFE Pfizer | Maintains: Neutral | $31 → $29 | $26.30 | +10.27% | 9 | Jan 8, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $89.50 | +34.08% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $50.69 | +40.07% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $109.95 | -12.69% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $484.24 | +21.01% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $303.01 | +7.59% | 7 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $140.64 | +43.63% | 10 | Oct 3, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $14 → $6 | $1.39 | +331.65% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $41 | $21.27 | +92.76% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.13 | +651.17% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $700.33 | +56.93% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $10.47 | +415.76% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $106.28 | +57.13% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $873.68 | -51.93% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $9.18 | -78.21% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.50 | +1,100.00% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $202.08 | -27.75% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $55.83 | +34.34% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.01 | +763.79% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $11.63 | -22.61% | 1 | Aug 23, 2021 |
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $6.29
Upside: +11.29%
ALX Oncology Holdings
Jan 27, 2025
Maintains: Buy
Price Target: $4 → $2.2
Current: $1.12
Upside: +96.43%
Pfizer
Jan 8, 2025
Maintains: Neutral
Price Target: $31 → $29
Current: $26.30
Upside: +10.27%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $89.50
Upside: +34.08%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $50.69
Upside: +40.07%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $109.95
Upside: -12.69%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $484.24
Upside: +21.01%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $303.01
Upside: +7.59%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $140.64
Upside: +43.63%
Acumen Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $14 → $6
Current: $1.39
Upside: +331.65%
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $21.27
Upside: +92.76%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.13
Upside: +651.17%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $700.33
Upside: +56.93%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $10.47
Upside: +415.76%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $106.28
Upside: +57.13%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $873.68
Upside: -51.93%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $9.18
Upside: -78.21%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.50
Upside: +1,100.00%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $202.08
Upside: -27.75%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $55.83
Upside: +34.34%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.01
Upside: +763.79%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $11.63
Upside: -22.61%